▸ 7 Oct 2026, 09:32 Further significant results from SNT-4728 iRBD Phase 2 trial Company Update
▸ 5 Oct 2026, 14:24 Notification regarding unquoted securities - SNT Securities Administration
▸ 5 Oct 2026, 14:21 Notification regarding unquoted securities - SNT Securities Administration
▸ 1 Oct 2026, 09:49 Syntara expands SNT-9465 skin scarring study Company Update
▸ 21 Sep 2026, 08:45 Syntara receives A$4.7m R&D Tax Incentive Company Update
▸ 15 Sep 2026, 10:01 Application for quotation of securities - SNT Securities Administration
▸ 15 Sep 2026, 09:58 Notification of 2026 AGM Date Meetings & Governance
▸ 27 Aug 2026, 14:50 Appendix 4G and Corporate Governance Statement Company Administration
▸ 27 Aug 2026, 14:49 Appendix 4E and Annual Report Financial Results
▸ 28 Jul 2026, 11:01 Investor Update Webinar Presentation Presentations
▸ 27 Jul 2026, 09:56 Investor Update Webinar Presentations
▸ 27 Jul 2026, 09:26 Investor Presentation Presentations
▸ 27 Jul 2026, 09:18 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 20 Jul 2026, 10:01 AZALOX MDS study advances to final Phase 1b cohort Company Update
▸ 6 Jul 2026, 13:13 SNT-4728 Webinar Presentation Presentations
▸ 6 Jul 2026, 09:43 Encouraging SNT-4728 Phase 2 iRBD results Company Update
▸ 3 Jul 2026, 09:23 Trading Halt Trading Halt / Suspension
▸ 2 Jul 2026, 15:14 Notification regarding unquoted securities - SNT Securities Administration
▸ 2 Jul 2026, 14:59 Application for quotation of securities - SNT Securities Administration
▸ 2 Jul 2026, 14:56 Proposed issue of securities to the CEO Company Administration
▸ 1 Jul 2026, 10:01 SNT-9465 scarring trial exceeds 50% enrolment Company Update
▸ 30 Jun 2026, 09:36 Change in substantial holding Substantial Holders
▸ 25 Jun 2026, 09:18 Section 708A(5)(e) notice Securities Administration
▸ 25 Jun 2026, 09:12 Application for quotation of securities - SNT Securities Administration
▸ 23 Jun 2026, 14:23 Results of Meeting Meetings & Governance
▸ 11 Jun 2026, 09:13 Application for quotation of securities - SNT Securities Administration
▸ 10 Jun 2026, 15:07 Results of Share Purchase Plan Capital Raising
▸ 1 Jun 2026, 11:44 SNT-4728 webinar presentation Presentations
▸ 28 May 2026, 10:08 SNT-4728 pre-readout informational webinar Company Update
▸ 19 May 2026, 10:04 Notice of General Meeting/Proxy Form Meetings & Governance
▸ 14 May 2026, 10:02 Update - Proposed issue of securities - SNT Securities Administration
▸ 14 May 2026, 09:02 Share Purchase Plan Offer Booklet Capital Raising
▸ 12 May 2026, 09:57 Change in substantial holding Substantial Holders
▸ 11 May 2026, 16:36 Change in substantial holding Substantial Holders
▸ 7 May 2026, 09:32 Section 708A(5)(e) notice Securities Administration
▸ 7 May 2026, 09:28 Application for quotation of securities - SNT Securities Administration
▸ 30 Apr 2026, 10:51 Investor Update Webinar Presentations
▸ 30 Apr 2026, 10:50 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 29 Apr 2026, 11:43 Investor update webinar Presentations
▸ 29 Apr 2026, 10:21 Proposed issue of securities - SNT Securities Administration
▸ 29 Apr 2026, 10:21 Proposed issue of securities - SNT Securities Administration
▸ 29 Apr 2026, 10:21 Equity Raising Presentation Presentations
▸ 29 Apr 2026, 10:21 $8m placement and share purchase plan Capital Raising
▸ 28 Apr 2026, 12:06 Continuation of trading halt Company Administration
▸ 28 Apr 2026, 12:06 Positive FDA feedback for Amsulostat P2b trial Company Update
▸ 27 Apr 2026, 09:22 Trading Halt Trading Halt / Suspension
▸ 13 Apr 2026, 08:46 Application for quotation of securities - SNT Securities Administration
▸ 7 Apr 2026, 13:49 Notification regarding unquoted securities - SNT Securities Administration
▸ 25 Mar 2026, 14:29 NWR Virtual Healthcare Conference Presentation Presentations
▸ 24 Mar 2026, 08:31 Syntara to present at NWR Virtual Healthcare Conference Presentations
▸ 19 Mar 2026, 09:11 SNT-4728 milestone payment received from Parkinsons UK Company Update
▸ 10 Mar 2026, 16:33 Notification of cessation of securities - SNT Securities Administration
▸ 27 Feb 2026, 13:22 Application for quotation of securities - SNT Securities Administration
▸ 26 Feb 2026, 08:34 Half Year Report and Appendix 4D Financial Results
▸ 23 Feb 2026, 13:44 Application for quotation of securities - SNT Securities Administration
▸ 18 Feb 2026, 10:57 Notification regarding unquoted securities - SNT Securities Administration
▸ 5 Feb 2026, 08:58 Investor Presentation Euroz Hartleys Healthcare Forum Presentations
▸ 3 Feb 2026, 10:37 2026 Outlook Webinar Presentation Presentations
▸ 2 Feb 2026, 10:32 Application for quotation of securities - SNT Securities Administration
▸ 29 Jan 2026, 10:20 2026 Outlook Webinar and Q&A Presentations
▸ 29 Jan 2026, 10:02 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 21 Jan 2026, 10:00 Amsulostat and Garvan in MRFF funded pancreatic trial Company Update
▸ 8 Jan 2026, 14:11 Notification regarding unquoted securities - SNT Securities Administration
▸ 8 Jan 2026, 14:03 Company Secretary Appointment/Resignation Company Administration
▸ 8 Jan 2026, 09:30 SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited Company Update
▸ 23 Dec 2025, 09:06 Letter to Shareholders Letters & Addresses
▸ 5 Dec 2025, 08:23 Amsulostat data to be presented at ASH Company Administration
▸ 26 Nov 2025, 11:07 SNT 9465 Webinar Presentations
▸ 26 Nov 2025, 09:20 Change of Director's Interest Notice - GP Director Interests
▸ 26 Nov 2025, 09:20 Change of Director's Interest Notice - KM Director Interests
▸ 26 Nov 2025, 09:19 Notification regarding unquoted securities - SNT Securities Administration
▸ 26 Nov 2025, 09:17 Notification regarding unquoted securities - SNT Securities Administration
▸ 26 Nov 2025, 09:17 Notification regarding unquoted securities - SNT Securities Administration
▸ 26 Nov 2025, 09:06 Skin scarring program to progress on positive Phase1a result Company Update
▸ 24 Nov 2025, 16:10 Topical Pan-Lox Inhibition for Skin Scarring KOL webinar Presentations
▸ 21 Nov 2025, 09:36 Initiation of amsulostat Phase 2 MESSAGE trial in MDS Company Update
▸ 20 Nov 2025, 11:19 Results of AGM Meetings & Governance
▸ 20 Nov 2025, 09:27 CEO Address to AGM and Shareholder Resolutions Presentations
▸ 20 Nov 2025, 09:25 Chair's Address to Shareholders Letters & Addresses
▸ 17 Nov 2025, 10:10 Positive opinion for Orphan Drug Designation in EU Company Update
▸ 28 Oct 2025, 08:30 Quarterly Shareholder Report and Appendix 4C Quarterly Reports
▸ 20 Oct 2025, 10:09 Notice of Annual General Meeting/Proxy Form Presentations
▸ 15 Oct 2025, 08:43 Investor Presentation HK Ignite Investment Summit Presentations
▸ 2 Oct 2025, 16:47 Notification regarding unquoted securities - SNT Securities Administration
▸ 1 Oct 2025, 09:45 Notice under ASX Listing Rule 3.13.1 Meetings & Governance
▸ 30 Sep 2025, 09:05 Positive final Phase 2a amsulostat data webinar presentation Presentations
▸ 30 Sep 2025, 08:26 Positive top-line Phase 2a data confirms competitive profile Company Update
▸ 30 Sep 2025, 08:25 Appoints global myelofibrosis experts to support amsulostat Company Administration
▸ 24 Sep 2025, 11:50 Receives A$5.6m R&D Tax Incentive Periodic Reports
▸ 9 Sep 2025, 08:27 Investor Presentation E&P Small Cap Healthcare Conference Presentations
▸ 1 Sep 2025, 08:43 Letter to shareholders - path forward for amsulostat Letters & Addresses
▸ 28 Aug 2025, 14:23 2025 Corporate Governance Statement Company Administration
▸ 28 Aug 2025, 14:21 Appendix 4G Key to Disclosures Company Administration
▸ 28 Aug 2025, 14:05 Annual Report to shareholders Financial Results
▸ 28 Aug 2025, 13:55 Preliminary Final Report Financial Results
▸ 28 Aug 2025, 10:32 Application for quotation of securities - SNT Securities Administration
▸ 19 Aug 2025, 11:50 TechKnow Investor Presentation Presentations
▸ 11 Aug 2025, 09:51 FDA guidance webinar Presentations
▸ 11 Aug 2025, 09:49 Guidance from FDA on amsulostat clinical progression Company Update
▸ 8 Aug 2025, 08:33 Application for quotation of securities - SNT Securities Administration